Intellia Therapeutics Reports Q3 2025 Financial Results with Increased Collaboration Revenue

Intellia Therapeutics, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a collaboration revenue of $13.8 million for the quarter, up from $9.1 million in the same period last year. For the nine months ended September 30, 2025, total collaboration revenue was $44.7 million, slightly down from $45.0 million in the prior year. The increase in quarterly revenue was primarily attributed to cost reimbursements from its collaboration with Regeneron Pharmaceuticals, while the annual decline was influenced by the recognition of $21.0 million in previously eliminated intra-entity profit in 2024.

Operating expenses for the third quarter decreased to $125.3 million from $153.9 million year-over-year, driven by a significant reduction in research and development costs, which fell to $94.7 million from $123.4 million. This reduction was largely due to a strategic restructuring that included a workforce reduction of approximately 27% in January 2025, resulting in lower employee-related expenses and stock-based compensation. The company reported a net loss of $101.3 million for the quarter, an improvement from a net loss of $135.7 million in the same quarter of 2024.

Intellia's total assets as of September 30, 2025, were $925.3 million, a decrease from $1.2 billion at the end of 2024. The decline in assets was primarily due to a reduction in marketable securities, which fell to $317.7 million from $412.3 million. The company's cash and cash equivalents increased slightly to $193.4 million from $189.2 million, reflecting a net cash inflow from financing activities, which totaled $129.5 million for the nine months ended September 30, 2025, primarily from at-the-market offerings.

In terms of operational developments, Intellia has been focusing on its lead in vivo programs, lonvo-z and nex-z, which are in advanced clinical stages for treating hereditary angioedema and ATTR amyloidosis, respectively. The company announced the completion of enrollment for the Phase 3 trial of lonvo-z and is preparing for a potential U.S. commercial launch in the first half of 2027. However, the nex-z program is currently on clinical hold due to safety concerns, which has prompted the company to suspend milestone guidance for this product.

Looking ahead, Intellia expects its current cash, cash equivalents, and marketable securities will be sufficient to fund its operations into mid-2027, covering ongoing expenses and capital requirements through the anticipated launch of lonvo-z. The company continues to prioritize its research and development efforts on high-value programs while navigating the challenges posed by its clinical hold and ongoing restructuring efforts.